Get the Stockscreener App
32.06
0.69%
0.22
Monopar Therapeutics Inc stock is traded at $32.06, with a volume of 70,898.
It is up +0.69% in the last 24 hours and down -29.10% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$31.84
Open:
$32
24h Volume:
70,898
Relative Volume:
1.91
Market Cap:
$197.81M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-13.94
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-10.22%
1M Performance:
-29.10%
6M Performance:
-20.35%
1Y Performance:
+1,062%
1-Day Range:
$31.32
$33.04
1-Week Range:
$31.32
$37.56
52-Week Range:
$2.25
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
32.06 | 211.38M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics Inc. Sees Relief Buying After Extended Drop2025 Price Action Summary & Verified Entry Point Detection - beatles.ru
Published on: 2025-08-20 15:21:29 - Newser
Is now a turning point for Monopar Therapeutics Inc.Weekly Earnings Recap & AI Enhanced Trading Signals - Newser
Monopar Therapeutics Inc. stock trend forecastPortfolio Return Report & Long-Term Safe Investment Ideas - Newser
Predicting Monopar Therapeutics Inc. trend using moving averagesTrade Entry Report & Verified Swing Trading Watchlist - Newser
What the charts say about Monopar Therapeutics Inc. todayWall Street Watch & Weekly Top Gainers Trade List - Newser
Will Monopar Therapeutics Inc. outperform the marketMarket Performance Report & Capital Protection Trading Alerts - Newser
Does Monopar Therapeutics Inc. fit your quant trading modelShare Buyback & Stock Portfolio Risk Management - Newser
Is Monopar Therapeutics Inc. stock reversal real or fakeEarnings Recap Report & Daily Growth Stock Tips - Newser
Using Bollinger Bands to evaluate Monopar Therapeutics Inc.July 2025 Recap & Safe Capital Growth Stock Tips - Newser
How to escape a deep drawdown in Monopar Therapeutics Inc.Earnings Recap Summary & Growth Focused Stock Reports - Newser
Using flow based indicators on Monopar Therapeutics Inc.Forecast Cut & Daily Entry Point Trade Alerts - Newser
Combining price and volume data for Monopar Therapeutics Inc.Quarterly Risk Review & Weekly Chart Analysis and Trade Guides - Newser
Is Monopar Therapeutics Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Review & High Accuracy Swing Trade Signals - Newser
Published on: 2025-08-19 16:09:52 - Newser
Published on: 2025-08-19 15:32:28 - Newser
Published on: 2025-08-19 04:10:08 - Newser
Monopar Therapeutics Inc. Flashes Rebound Signal in Oversold ConditionJuly 2025 Price Swings & Entry and Exit Point Strategies - beatles.ru
Monopar Therapeutics Inc. stock trendline breakdown2025 AllTime Highs & Safe Capital Growth Tips - Newser
What is Chardan Capital’s Forecast for MNPR FY2025 Earnings? - Defense World
Will breakout in Monopar Therapeutics Inc. lead to full recovery2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Strategies to average down on Monopar Therapeutics Inc.2025 Market Trends & Accurate Buy Signal Alerts - Newser
Will Monopar Therapeutics Inc. price bounce be sustainableJuly 2025 Momentum & Short-Term High Return Strategies - Newser
Published on: 2025-08-17 23:12:58 - newsyoung.net
MNPR FY2025 EPS Increased by Brookline Capital Management - Defense World
How to use a screener to detect Monopar Therapeutics Inc. breakoutsJuly 2025 Action & Long-Term Growth Stock Strategies - Newser
What makes Monopar Therapeutics Inc. stock price move sharplyFed Meeting & Smart Money Movement Tracker - Newser
Chart based exit strategy for Monopar Therapeutics Inc.Portfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Can swing trading help recover from Monopar Therapeutics Inc. lossesMarket Rally & AI Enhanced Execution Alerts - Newser
Will Volume Confirm Reversal in Monopar Therapeutics Inc.Quarterly Growth Report & Real-Time Chart Breakout Alerts - newsyoung.net
Traders Consider Averaging Down in Monopar Therapeutics Inc.July 2025 Short Interest & Verified Chart Pattern Signals - metal.it
Is it too late to sell Monopar Therapeutics Inc.July 2025 PostEarnings & Community Verified Trade Signals - Newser
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):